Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer. [electronic resource]
Producer: 20210104Description: 286 p. digitalISSN:- 1471-2407
- Aged
- Aged, 80 and over
- Androstadienes -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab -- administration & dosage
- Breast Neoplasms -- drug therapy
- Capecitabine -- administration & dosage
- Cross-Over Studies
- Estrogen Receptor alpha -- metabolism
- Everolimus -- administration & dosage
- Female
- Humans
- Middle Aged
- Patient Preference -- statistics & numerical data
- Prognosis
- Quality of Life
- Receptor, ErbB-2 -- metabolism
- Receptors, Progesterone -- metabolism
- Survival Rate
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.